The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI.
 
Jakob Hagen Vasehus Schou
No Relationships to Disclose
 
Nicklas Roest
Employment - Scandion Oncology
Leadership - Scandion Oncology
Stock and Other Ownership Interests - Scandion Oncology; Scandion Oncology (I)
Consulting or Advisory Role - WntResearch
Patents, Royalties, Other Intellectual Property - Scandion Oncology
 
Morten Ladekarl
Research Funding - Debiopharm Group (Inst); Scandion Oncology (Inst); SERVIER (Inst)
 
Jens Bo Rode Hansen
Employment - Scandion Oncology
Leadership - Scandion Oncology
Stock and Other Ownership Interests - Roche; Scandion Oncology
Patents, Royalties, Other Intellectual Property - Roche
 
Maj Hedtjaern
Employment - Scandion Oncology
Leadership - Scandion Oncology
Stock and Other Ownership Interests - Roche; Scandion Oncology
Consulting or Advisory Role - Lipigon; Scandion Oncology
Other Relationship - Novo Nordisk (I)
 
Peter Michael Vestlev
Employment - Scandion Oncology
Leadership - Scandion Oncology
Stock and Other Ownership Interests - AstraZeneca; Lundbeck; Novo Nordisk; Scandion Oncology; Scandion Oncology (I)
Patents, Royalties, Other Intellectual Property - patent pending
Other Relationship - MSD